State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Bhatt DL, Mas JL, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health (REACH) Registry Eur Heart J 2009;30:2318-26
   PubMed Web of Science ®Google Scholar
• Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 2010;85:678-92
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-228
   PubMed Web of Science ®Google Scholar
• Allemang MT, Rajani RR, Nelson PR, et al. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg 2013;27:62-7
   PubMed Web of Science ®Google Scholar
• Jahn R, Diehm C, Lux G, et al. Effect of guideline orientation on the outcomes of peripheral arterial disease in primary care. Curr Med Res Opin 2011;27:1183-90
   PubMed Web of Science ®Google Scholar
• Zontivity (vorapaxar) tablets. Full Prescribing Information. FDA Label. Initial US Approval: 2014. Revised May. Silver Spring, MD: Food and Drug Administration, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204886s000lbl.pdf [Last accessed 28 January 2015]
   Google Scholar
• Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013;127:1522-29, 1529e1521-26
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica B, Fox K, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J 2009;158:335-41
   PubMed Web of Science ®Google Scholar
• Whalen JD, Davies G, Du M, et al. A state transition model for health outcomes associated with vorapaxar treatment as an add-on to standard care antiplatelet therapy in the prevention of thrombotic events for patients with a recent myocardial infarction. Am J Cardiovasc Drugs 2016;16:285-95
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Bagust A, Boland A, et al. Ticagrelor for the treatment of acute coronary syndromes: a Single Technology Appraisal. Report commissioned by the NIHR HTA Programme as project number 08/240 Liverpool, UK: Liverpool Reviews and Implementation Group (LRiG), The University of Liverpool, 2011. Available at: http://www.nice.org.uk/guidance/ta236/documents/acute-coronary-syndromes-ticagrelor-evidence-review-group-report2 [Last accessed 28 January 2015]
   Google Scholar
• Greenhalgh J, Bagust A, Boland A, et al. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Liverpool Reviews and Implementation Group (LRiG), The University of Liverpool. Health Technol Assess 2010;14(Suppl 1):31-8
   PubMed Web of Science ®Google Scholar
• TRA 2°P Clinical Study Report. Event Count Data for Qualifying MI and Qualifying PAD cohorts, Data on File
   Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Hsieh AF, Kulkarni VT, et al. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ 2015;350:h411
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012;380:1317-24
   PubMed Web of Science ®Google Scholar
• Bittl JA, Hirsch AT. Concomitant peripheral arterial disease and coronary artery disease: therapeutic opportunities. Circulation 2004;109:3136-44
   PubMed Web of Science ®Google Scholar
• Sabouret P, Cacoub P, Dallongeville J, et al. REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year. Arch Cardiovasc Dis 2008;101:81-8
   PubMed Web of Science ®Google Scholar
• United States Social Security Administration. Social Security: Period Life Table, 2011. Silver Spring, MD: United States Social Security Administration, 2012. Available at: https://www.ssa.gov/oact/STATS/table4c6.html [Last accessed 30 May 2014]
   Google Scholar
• Center for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System. Deaths, Percent of Total Deaths, and Death Rates for the 15 Leading Causes of Death in 5-year Age Groups, by Race and Sex: United States, 2013. Table LCWK1. Atlanta, GA: Center for Disease Control and Prevention, 2014. Available at: http://www.cdc.gov/nchs/nvss/mortality/lcwk1.htm [Last accessed 30 May 2014]
   Google Scholar
• Linfante I, Starosciak AK, Walker GR, et al. Predictors of poor outcome despite recanalization: a multiple regression analysis of the NASA registry. J Neurointerv Surg 2016;8:224-9
   PubMed Web of Science ®Google Scholar
• Bronnum-Hansen H, Davidsen M, Thorvaldsen P, et al. Long-term survival and causes of death after stroke. Stroke 2001;32:2131-6
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess 2011;15:1-178
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Cooperation and Development (OECD). Health at a Glance 2013 – OECD Indicators. Paris: OECD Publishing, 2013. Available at: http://dx.doi.org/10.1787/health_glance-2013-en [Last accessed 30 May 2014]
   Google Scholar
• Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation 2016;134:304-13
   PubMed Web of Science ®Google Scholar
• Swaminathan A, Vemulapalli S, Patel MR, et al. Lower extremity amputation in peripheral artery disease: improving patient outcomes. Vasc Health Risk Manag 2014;10:417-24
   PubMedGoogle Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333-41
   PubMed Web of Science ®Google Scholar
• Banerjee S, Brown A, McGahan L, et al. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses. CADTH Technol Overv 2012;2:e2102
   PubMedGoogle Scholar